Investors should view the recent "Peptide FUD" as a high-conviction buying opportunity for Hims & Hers Health (HIMS), which currently trades at an attractive valuation of roughly 3x gross profit. As the dominant leader in U.S. telehealth with nearly 50% market share, HIMS is positioned to disrupt traditional retail pharmacies through its vertically integrated, insurance-free subscription model. The stock is currently priced under $35, but anticipated guidance updates and 35% revenue growth suggest significant upside as the market begins to price in its GLP-1 and compounding potential. Focus on the company's shift toward customized medicine and painless lab testing, which creates a "sticky" ecosystem with 90% recurring revenue similar to a high-growth software business. Ignore short-term regulatory noise from big pharma, as HIMS is the primary consolidator in a fragmented digital pharmacy sector that is more resilient to AI disruption than pure software plays.

Hims & Hers Health, Inc. (HIMS)

• HIMS is currently facing "Peptide FUD" (Fear, Uncertainty, and Doubt) and lukewarm analyst ratings from firms like Bank of America and Truist, causing the stock to drop approximately 7% in a week. • The core of the recent controversy involves big pharma's push to restrict compounding and peptides to protect their own patented versions of GLP-1 drugs. • The speaker argues that HIMS is the absolute leader in U.S. telehealth with nearly a 50% market share, significantly ahead of competitors like Ro (12-13% share). • Business Model Strengths: * 90% Recurring Revenue: Operates similarly to a SaaS (Software as a Service) business but with a physical product (pills/medications). * Vertical Integration: Combines an e-doctor, e-pharmacy, and e-labs into one platform. * No Insurance Model: By bypassing insurance, HIMS avoids "gatekeepers," offers transparent upfront pricing, and provides medications that are often cheaper than traditional insurance co-pays. * Customization: Offers personalized dosages (e.g., specific milligram counts) that traditional pharma companies do not provide. * Zero-to-One Innovation: Recent acquisitions include Eucalyptus and a company specializing in painless micro-needles to increase customer compliance for lab testing.

Takeaways

• Valuation Opportunity: The stock is described as "way too cheap," trading at roughly 3x gross profit and 24x EBITDA. The speaker notes the stock is currently under $35, whereas it traded between $50-$70 in 2025 (likely a reference to a prior peak or projected cycle) when the company had fewer products and a weaker competitive position. • Growth Potential: Revenue growth is estimated at 35% (mid-range estimate), and the speaker anticipates a major guidance update that could make the stock look even cheaper. • Market Misunderstanding: Wall Street may be mispricing the stock by treating it as a traditional healthcare company rather than a high-growth digital disruptor. The speaker compares this "misunderstanding" to the early years of Amazon. • Risk Mitigation: While big pharma may attempt to delay peptide compounding through regulatory fights, the speaker believes progress is inevitable, comparing the disruption to Uber vs. taxis or Netflix vs. cable.

GLP-1s & Peptides

• Peptides are small chains of amino acids that are naturally occurring and difficult to patent unless modified. • Big pharma companies modify these compounds (e.g., to prevent stomach acid degradation) to gain regulatory capture and charge higher prices. • HIMS utilizes compounding to offer these treatments, which is the current source of legal and regulatory tension in the market.

Takeaways

• Sentiment: The speaker views the "Peptide FUD" as a temporary hurdle or delay rather than a structural failure of the business model. • Pricing: The speaker argues that the potential of the peptide business is not yet priced into the stock, meaning any success in this vertical represents significant upside.

Telehealth & Digital Pharmacy Sector

• The sector is highly fragmented with many "teeny tiny players." • The industry is shifting toward customized medicine and transparent pricing, moving away from the "one-size-fits-all" approach of traditional retail pharmacies. • Physical vs. AI: Because the business involves physical products (medications), it is viewed as more resilient to AI disruption than pure software businesses.

Takeaways

• Consolidation: HIMS is positioned as the "large consolidator" in the space, likely to absorb market share from the 45,000 retail pharmacies and "mom-and-pop" doctors currently being disrupted. • Investment Theme: Look for companies that bundle doctor visits, follow-ups, and prescriptions into a single monthly subscription, as this "bundled" model is gaining consumer favor over traditional insurance-led models.